Mitsubishi Tanabe Eyes M&As for Post-Radicava Strategy in US: President

May 11, 2017
Mitsubishi Tanabe President Masayuki Mitsuka Buoyed by the recent FDA nod for its amyotrophic lateral sclerosis (ALS) drug Radicava (edaravone), Mitsubishi Tanabe Pharma is to kick start its US operations revolving around neurology and autoimmune diseases, with M&As also on...read more